Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
### Primary Indications
* Gastroesophageal reflux disease (GERD)
* Erosive esophagitis healing and maintenance
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* H. pylori eradication (in combination regimens)
### Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally once daily. May increase to 40 mg twice daily for severe cases.
* **Pathological Hypersecretory Conditions:** Starting dose is typically 40 mg orally twice daily. Doses may be titrated upwards based on clinical response, with doses up to 120 mg twice daily administered intravenously. Oral doses may exceed 40 mg once daily.
* **H. pylori Eradication:** 40 mg orally twice daily for 7-14 days in combination with antibiotics.
### Pediatric Dosing
* **GERD/Erosive Esophagitis:**
* **1 year and older:** 20-40 mg orally once daily, depending on weight and severity.
* 1-5 years (15 kg to <25 kg): 20 mg once daily.
* 5-12 years (25 kg to <40 kg): 20-40 mg once daily.
* 12 years and older (≥40 kg): 40 mg once daily.
* Dosing may be adjusted based on clinical response.
### Dose Adjustments
* **Hepatic Impairment:** Maximum daily dose is 40 mg orally once daily.
* **Renal Impairment:** No dose adjustment is typically needed.
### Contraindications
* Hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation.
### Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, flatulence, dizziness.
Serious: Clostridium difficile-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia (can be severe and prolonged), vitamin B12 deficiency, lupus erythematosus (cutaneously or systemically).
### Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, iron salts, clopidogrel (reduced efficacy).
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 substrates:** Consider potential for altered pharmacokinetics.
### Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., muscle cramps, seizures, tremors, arrhythmias).
* Monitor for signs of C. difficile infection.
* Consider monitoring vitamin B12 levels with prolonged therapy.
* Monitor bone mineral density with long-term therapy, especially in patients with risk factors for osteoporosis.
### Clinical Pearls
* Administer orally 30-60 minutes before a meal.
* For patients who have difficulty swallowing, pantoprazole delayed-release oral suspension is available.
* IV formulation is available for patients unable to take oral medication.
* Long-term PPI use is associated with increased risk of fractures, C. difficile infection, and hypomagnesemia. Discontinue or use the lowest effective dose.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional protocols for definitive guidance.*
